Folate absorption in women with a history of neural tube defect-affected pregnancy

• Published in: The American journal of clinical nutrition Vol. 72; no. 1; pp. 154 - 158
• Main Authors: BODDIE, A. M, DEDLOW, E. R, NACKASHI, J. A, OPALKO, F. J, KAUWELL, G. P. A, GREGORY, J. F, BAILEY, L. B
• Format: Journal Article
• Language: English
• Published: Bethesda, MD American Society for Clinical Nutrition 01-07-2000; American Society for Clinical Nutrition, Inc
• Subjects: Administration, Oral; Adult; Biological and medical sciences; Birth defects; Carbon Isotopes; Case-Control Studies; Diet; Diseases of mother, fetus and pregnancy; Female; Folic Acid - administration & dosage; Folic Acid - blood; Folic Acid - pharmacokinetics; Gynecology. Andrology. Obstetrics; Humans; Intestinal Absorption - physiology; Medical sciences; Neural Tube Defects - prevention & control; Neurological disorders; Pregnancy; Pregnancy. Fetus. Placenta; Pteroylpolyglutamic Acids - pharmacokinetics; Pteroylpolyglutamic Acids - urine; Vitamin B; Women; Womens history; Human; Nervous system diseases; Congenital; Closure; Pregnancy disorders; Diseases of the osteoarticular system; Bioavailability; Folic acid; Folate; Absorption; Neural tube; Malformation; Female; Isotopes
• ISSN: 0002-9165; 1938-3207
• DOI: 10.1093/ajcn/72.1.154

The risk of neural tube defects (NTDs) is significantly reduced by supplemental folic acid. NTD risk may be associated with impaired absorption of polyglutamyl folate, the primary form of naturally occurring food folate, and of folic acid in supplements or fortified food. Stable-isotope methods provide the specificity needed to test this hypothesis.
We determined whether women who had an NTD-affected pregnancy had a reduced ability compared with control women to absorb polyglutamyl folate relative to folic acid.
Healthy, nonpregnant women with a history of an NTD-affected pregnancy (cases; n = 11) and control women (n = 11) were administered an oral dose containing a mixture of [(2)H]pteroylpentaglutamate ([(2)H(2)]PteGlu(5); 233 nmol) and [(13)C]pteroylmonoglutamate ([(13)C(5)]PteGlu(1); 567 nmol) after a 30-d saturation protocol (2 mg unlabeled folic acid/d). Relative extents of absorption were evaluated by urinary excretion of (2)H(2)- and (13)C(5)-labeled folates 48 h postdose.
During the first 24 h postdose, cases excreted less (f1.gif" BORDER="0"> +/- SD) [(2)H(2)]PteGlu(5) (21 +/- 12% compared with 37 +/- 19%; P = 0.01) and [(13)C(5)]PteGlu(1) (17 +/- 8% compared with 31 +/- 14%; P = 0.007) than did controls. No significant differences between cases and controls were detected in the percentage of [(2)H(2)]PteGlu(5) or [(13)C(5)]PteGlu(1) excreted during the second 24 h postdose or when the data were averaged over 48 h. However, excretion of the [(2)H(2)]folates tended to be lower in cases than in controls over the 48-h period (33 +/- 13% compared with 45 +/- 26%; P = 0.21). A similar trend (P = 0.29) for lower excretion of [(13)C(5)]folates in cases was also observed (31 +/- 16% compared with 39 +/- 17%). The ratio of urinary [(2)H(2)]folates to [(13)C(5)]folates did not differ significantly between cases and controls.
These data suggest the need for a larger-scale study using stable-isotope methods to further investigate this hypothesis.